Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q2 EPS of ($0.36), $0.40 better than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.